INTRODUCTION
M atrix controlled release formulations are getting much attention in recent past due to higher clinical effi cacy and patient compliance. Consequently, a range of controlled release dosage forms have been developed or are under development for the treatment of chronic conditions like hypertension. Th e ultimate aim in the design of an oral controlled release dosage form includes maintaining relatively constant therapeutic blood levels of the drug for a desired period, reduce dosing frequency, improve patient compliance and decrease incidences of adverse drug reactions (1) . Pharmaceutical literature suggests that hydrophilic matrix system is widely used for the modifi cation of drug release in oral therapy because of its simplicity in manufacture (2) (3) . In such a system, the drug release is controlled by a combination of several physical processes which include, but are not limited to, diffusion, polymer swelling, erosion and dissolution. A successful hydrophilic matrix system should possess a polymer that will wet, hydrate and swell to form a gelatinous layer and avoid disintegration of the tablet. To achieve this, diff erent cellulose derivatives or their combinations have been extensively used in the preparation of matrix tablets. Hydroxy propyl methyl cellulose (HPMC) is the most widely studied hydrophilic swellable matrix forming material for the preparation of modifi ed drug release products. Its popularity can be attributed to the polymer's non-toxic nature, small infl uence of processing variables on drug release, ease of compression, and its capability to accommodate high levels of drug loading (1, 4) . Hypertension being a chronic disorder requires a steady state concentration through out the treatment. Enalapril maleate (EM), an ACE inhibitor is commonly administered orally during the treatment for hypertension. However, due to its low oral bioavailability (41%), short biological half life and narrow therapeutic concentration, the dosing management of the drug has become convoluted (5) . Th e objective of the present study was to formulate and evaluate a controlled release matrix uncoated tablets for EM using varying viscosity grades of HPMC (K100 and K4M).
MATERIALS AND METHODS

Materials
EM (Ranbaxy, Gurgaon, India), HPMC K100 and HPMC K4M (Colorcon, Goa, India) were received as gratis samples. All other additives like acetonitrile and water (HPLC grade), spray dried lactose, poly vinyl pyrrolidone K30, magnesium stearate were procured commercially.
Preparation of matrix tablet of Enalapril maleate
Th e detailed compositions of EM matrix tablet formulations are given in Table 1 . Matrix tablets were prepared by direct compression method. Th e respective powders (drug, polymer, and additives) were passed through a sieve no. 60 (250 μm) and blended with a turbula mixer. All the batches were compressed on 10 station tablet machine (Cadmach, Ahmedabad, India) with 9 mm fl at round punches. Th ree batches were prepared for each formulation.
Characterization of tablets
Th e weight variation of the tablets were performed by randomly selecting twenty tablets and weighed individually and together in a single pan balance (Shimadzu, AX200, Japan). Friability was tested by Roche friabilator (Electro Lab, EF-2, Mumbai, India). Preweighed tablets were allowed for 100 revolutions in four minutes and were dusted. Th e percentage loss was calculated by reweighing the tablets. Hardness was tested by commonly used Monsanto type tablet hardness tester (IEC, Mumbai, India) by placing a tablet between the anvils and the crushing strength, which causes the tablet to break, was recorded. Th e thickness of the tablets was measured with a vernier caliper (6) .
Drug content studies
Th e drug content in tablets were determined by randomly choosing fi ve tablets of each formulation and thinly minced in a mortar separately. A quantity equivalent of 10 mg of EM was weighed, dissolved in mobile phase diluted suitably. Th e amount of drug was determined by injecting 20 μl of the sample in a high performance liquid chromatography system (HPLC; Shimadzu, LC-10ATVP, Kyoto, Japan). Th e HPLC system consists of a Phenomenex C18 analytical column (4.6 × 250 mm, Luna, 5.0 μm). Th e column was maintained at ambient temperature. Th e compounds were eluted at a fl ow rate of 1 ml/min using a mobile phase of acetonitrile-water (20:80) (7) . Th e column effl uent was monitored at 215 nm and the retention time was found to be 2.2 min. Th e method was validated by determination of linearity, precision, and accuracy. Th e range for the calibration curve was 4 − 800 ng/mL (R 2 = 0.98). Th e coeffi cient of variation and the relative error ranged 0.61− 5.93% and -0.62 − -8.52%, respectively.
In vitro drug dissolution studies
Drug release was evaluated in vitro using USP XIII Type II dissolution test apparatus (Electro Lab, TDT-08L, Mumbai). Th e dissolution for all the formulations was carried out in 750 ml 0.1 N HCl for fi rst 2 h and then made to 1000 ml with phosphate buff er to a pH of 6.8 and for a period of 12 h (8) . Th e temperature was maintained at 37 ± 0.5°C and a constant paddle rotation speed of 50 rpm. Sink condition was maintained throughout the studies. Samples (5 ml) were withdrawn at regular intervals and fi ltered through membrane fi lter (pore size 0.22 μm). Th e sample solutions were further diluted and analyzed for EM by HPLC method as previously described in drug content studies. 
Kinetics of drug release
Th e in vitro release data of the controlled release matrix tablets were evaluated kinetically by zero order kinetics, fi rst order kinetics, Higuchi models and Hixson Crowell and the ideal kinetic models were estimated for drug release using the following equations (9) . Zero order kinetics: 
Statistical analysis
All the data obtained for dissolution and drug content were evaluated statistically. Th e data were tested by one-way analysis of variance (ANOVA) and t-test using Graphpad prism 5, graphpad software, Inc., CA, USA, to test the eff ects of various treatments. P value less than 0.05 was considered statistically signifi cant. Th e data points provided in the graph is an average of six trials. Th e error bars represents the standard deviation.
RESULTS AND DISCUSSION
HPMC is the most widely used polymer for oral controlled delivery due to its pH independent drug release (10) . Its mechanism is well known as a swelling controlled release system and the release of hydrophilic drugs from this polymer is by diff usion process (11) . Generally it is used in combination with other polymers. In this study we have used two grades of HPMC (K100 and K4M) with varying quantities. Spray-dried lactose, polyvinyl pyrrolidone K30, and magnesium stearate are used as diluent, binder, and lubricant, respectively. Four formulations of EM controlled-release matrix tablets were prepared by direct compression technique. Th e total weight of the formulation was kept constant (300 mg), while the amount of HPMC and spray dried lactose were varied. As an ideal controlled release formulation should contain polymers the least possible amount and release the content in a controlled manner over a reasonable time, therefore a minimum quantity of polymers were used (Table 1) .
Th e physical properties of compressed controlled release tablets, such as weight variation, friability, hardness, and thickness, were determined by using standard protocols. Th e results obtained were recorded in Table 2 . It can be seen that the weight variation obtained for all the formulations were well in the range of offi cial limit. Th e friability studies revealed that there was no significant diff erence among the formulations and have good physical integrity ( Table 2) . Th e hardness of the tablets also did not vary signifi cantly (4.02-4.95 kg/cm 2 ). Similarly, no signifi cant diff erences in thickness values were observed between diff erent formulations. Th e drug content study proved that all the formulations had a better uniformity, and the assay values were statistically insignifi cant. Th e amount of drug in the formulations did not vary by more than 2% and were in the range of 98.27 to 101.48%. According to the theoretical release profi le worked out by using the pharmacokinetic data, a constant supply of 2.97 mg/h (7.42% per hour for 40 mg dosage) is required to be released (desired release). Fig. 1 represents the in vitro drug release profi les of all the four prepared formulations of controlled release matrix tablets. It is evident from the fi gure that the drug release (through out the study period) by the prepared formulations were more or less steady. In formulation E1, where greater amount of HPMC K100 (25 mg/tablet) was used when compared to K4M (5 mg/tablet), the release rate was higher from the initial period with greater amount being released (>90%) in 6 h. Hence in the next batch (E2), the quantity of polymer was interchanged, i.e., HPMC K100 (5 mg/tablet) and K4M (25 mg/tablet). Fig. 1 also indicated that the increase in the K4M quantity could not yield the desired release profi le, but the extent of drug release was reduced when compared to formulation E1. Th is data suggests that the concentration of polymers (HPMC K 100 and K4M) used were inadequate to control the release of EM.
Hence, another two batches of matrix tablets were prepared with greater amount of polymers [HPMC K100 (25 mg/tablet) and K4M (15 mg/ tablet) in batch E3 and HPMC K100 (15 mg/tablet) and K4M (25 mg/tablet) in batch E4]. Interestingly, the required amount of drug release was observed in formulation E3 (Figure 1) , through out the study period (14 h). Th e basic diff erence between E1 and E3 formulation is regarding the amount of HPMC K4M, greater amount (3 fold) with the latter. Th us the slow release of EM from E3 could be essentially due to the HPMC K4M (polymer) characteristics (high concentration, high viscosity, high molecular weight, greater binding capacity and superior cross linking), in the current experimental condition. Further, the release was signifi cantly controlled in formulation E4, but required drug release was not achieved in the initial stage of the study. Th e above data suggests that the increase in high molecular weight HPMC polymer concentration could reduce the drug release signifi cantly. Separately, the percentage of drug released from formulations E1, E2, E3 and E4 at 6 h were found to be 81, 65, 57 and 50%, respectively (Figure 1) .
Further, the prepared formulations were analyzed for the drug release kinetically. Th e calculated regression coeffi cients showed higher r 2 value with Higuchi models and the values were 0.953, 0.950, 0.997 and 0.995 for formulations E1, E2, E3 and E4, respectively. When analyzed for zero order, the r 2 values were found to be 0.910, 0.951, 0.984 and 0.987 for E1, E2, E3 and E4 formulations, respectively. However, the regression values were found to be low with fi rst order kinetics and Hixson Crowell models. Th us, both zero-order and Higuchi models could be applicable, although the drug release from the formulation E3 showed acceptable linearity (higher r 2 value for the whole release process) and fi t with the Higuchi model equation of diff usion from the matrix. In nutshell, it can be concluded that using HPMC in diff erent grades with low concentration alone can control; the EM release for a period of 14 h and the dissolution follows Higuchi model. 
